Professor Gareth Griffiths
天发娱乐棋牌_天发娱乐APP-官网|下载 Clinical Trials Unit director
Immunotherapy is the future of cancer treatment.
天发娱乐棋牌_天发娱乐APP-官网|下载 centre is dedicated to immunology. We use this knowledge to develop new immunotherapy treatments for cancer.
We develop these new immunotherapy treatments with the help of generous donors, patients on our trials, and researchers and clinicians across the University, UK and the world.
The new cancer treatments we are developing
天发娱乐棋牌_天发娱乐APP-官网|下载 scientists are:
- engineering new antibody drugs that help our immune system destroy or prevent the growth of cancer cells
- researching new treatments such as checkpoint inhibitor drugs which cause the body's T cells to find and kill cancer cells
- pioneering new approaches to stimulate different immune cells to improve cancer treatments
Clinical trials we are running
天发娱乐棋牌_天发娱乐APP-官网|下载 天发娱乐棋牌_天发娱乐APP-官网|下载 Clinical Trials Unit is evaluating the effectiveness of treatments such as:
- an immunotherapy treatment (durvalumab) in boosting the immune systems of people with bladder cancer after radiotherapy treatment
- a checkpoint inhibitor drug (pembrolizumab) in helping to treat diffuse large B cell lymphoma
- a vaccine for HPV-positive (human papilloma virus) people with cancer, called RNA
Researchers, find out more about our current clinical trials, including cancer treatments.
Patients, find out how to take part in a trial.
天发娱乐棋牌_天发娱乐APP-官网|下载 work across the University
The Centre for Cancer Immunology works with scientists, mathematicians, data experts and engineers from across the University to develop better treatments for cancer.
Collaborators are based both within the Faculty of Medicine at the 天发娱乐棋牌_天发娱乐APP-官网|下载 General Hopsital site and in other Highfield campus faculties — some at the Institute of Life Sciences.
To work with us to tackle cancer, check our current job opportunities (searching for Centre for Cancer Immunology).